Director, Discovery DMPK

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable.

The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigationalmedicine,zolucatetide, is the first and only direct inhibitor of theβ-catenin:

TCFinteraction,a central node in theWnt/β-catenin pathway that haseluded drug developers for decades.

Zolucatetideis being evaluated in the clinic across multiple

Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) anda rangeofothersolid tumor indications. Beyondzolucatetide,Parabilisis advancing additional

Helicon-based programs focused on other challenging targets where we believeourmedicines could have life-altering impact. For more information, visit  or follow us on Linked In.

Parabilis Medicines’ Drug Metabolism and Pharmacokinetics (DMPK) team is seeking an experienced Director-level scientist to provide strategic and scientific leadership across our portfolio of innovative peptide therapeutics. Reporting to the VP of Discovery DMPK, you will serve as a senior DMPK leader and primary representative across cross-functional discovery project teams, shaping DMPK strategy, play a key role in building an AI native organization and influencing key program decisions.

You will partner closely with medicinal chemists, pharmacologists, toxicologists, and external CRO partners to integrate ADME, PK, and PK/PD insights, proactively identify and mitigate development risks, and advance novel therapeutics from early discovery through development candidate nomination.

• Provide strategic leadership for peptide DMPK across multiple discovery programs, establishing ADME strategy and ensuring alignment with program milestones, development objectives, and broader portfolio priorities.
• Lead the design, interpretation, and integration of in vitro and in vivo ADME/PK studies to drive lead optimization, development candidate nomination, and progression into IND-enabling development.
• Serve as a DMPK subject matter expert and strategic partner to medicinal chemistry, pharmacology, toxicology, and other cross-functional functions, integrating DMPK data to influence chemical design and prioritize novel chemical matter with favorable drug-like and translational properties.
• Identify and proactively address key DMPK risks, knowledge gaps, and development challenges, establishing fit-for-purpose strategies to enable program progression.
• Provide scientific oversight of external CROs and partners, ensuring high-quality execution of DMPK studies within program timelines and budgets.
• Present DMPK strategies, integrated data assessments, human translation considerations, and risk/benefit recommendations to project teams and senior leadership to inform key investment and development decisions.
• Provide DMPK leadership for regulatory strategy and submissions, including IND/NDA, Investigator Brochures, briefing documents, and responses to regulatory authorities.
• Co-lead the development and implementation of AI-enabled DMPK workflows and digital solutions to streamline operations, accelerate data analysis and integration, and enable faster, data-driven decision-making across discovery and development programs.
• Build and advance DMPK capabilities in bioanalysis and peptide transporter sciences by strategically leveraging internal expertise, external partners, CROs, and emerging technologies to address program…